Michelle Ellis-Hutchings

Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.

Robert B. Lobell, CharlesA. Omer, Marc Abrams et al. · PubMed · 2001 · 239 citations

Medicine, Oncology, Pharmacology +16

3-Aminopyrrolidinone Farnesyltransferase Inhibitors:  Design of Macrocyclic Compounds with Improved Pharmacokinetics and Excellent Cell Potency

Ian M. Bell, Steven N. Gallicchio, Marc Abrams et al. · Journal of Medicinal Chemistry · 2002 · 85 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Dual Protein Farnesyltransferase−Geranylgeranyltransferase-I Inhibitors as Potential Cancer Chemotherapeutic Agents

S. J. DESOLMS, Terrence M. Ciccarone, Suzanne C. MacTough et al. · Journal of Medicinal Chemistry · 2003 · 60 citations · Full text

Medicine, Oncology, Pharmacology +9

Design and Biological Activity of (<i>S</i>)-4-(5-{[1-(3-Chlorobenzyl)-2- oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-Aminopyrrolidinone Farnesyltransferase Inhibitor with Excellent Cell Potency

Ian M. Bell, Steven N. Gallicchio, Marc Abrams et al. · Journal of Medicinal Chemistry · 2001 · 43 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Potent inhibitors of farnesyltransferase and geranylgeranyltransferase-I

Diem N. Nguyen, Craig A. Stump, Eileen S. Walsh et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 22 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +4